Cardiorenal syndrome type 4: Insights on clinical presentation and pathophysiology from the eleventh consensus conference of the acute dialysis quality initiative (ADQI)

Contributions to Nephrology

Volumn 182, Issue , 2013, Pages 158-173

  Tumlin, James A ^a   Costanzo, Maria R ^b   Chawla, Lakhmir S ^c   Herzog, Charles A ^d   Kellum, John A ^e   McCullough, Peter A ^f,g,h,i   Ronco, Claudio ^j  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b Edward Heart Hospital   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f St John Providence Health System   (United States)

^g Medical Centers   (United States)

^h St John Macomb Oakland Hospital   (United States)

ⁱ ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^j SAN BORTOLO HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; GALECTIN 3;

BLOOD VESSEL CALCIFICATION; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLASSIFICATION; CONSENSUS DEVELOPMENT; CORONARY ARTERY DISEASE; FIBROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; REVIEW; STANDARD;

CARDIO-RENAL SYNDROME; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FIBROBLAST GROWTH FACTORS; FIBROSIS; GALECTIN 3; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84879085945     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000349972     Document Type: Review

References (49)

1. Redón J, Cea-Calvo L, Lozano JV, Fernández-Pérez C, Navarro J, Bonet A, González-Esteban J, ERIC-HTA 2003 Study Investigators: Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens 2006; 24: 663-669.
2. Mathew K, Garratt N, Holmes DR, Best PJ, Singh M, Bell MR, Barsness GW, Verghese C, Rihal S, Textor SC, Grill DE, Berger PB, Ting HH: Coronary intervention incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264. (Pubitemid 34535335)
3. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N: Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31: 703-771.
4. Go AS, Chertow GM, Dongjie Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
5. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M: Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001; 37: 1191-1200. (Pubitemid 32525155)
6. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295. (Pubitemid 39258422)
7. Rostand SG, Kirk KA, Rutsky EA: Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984; 25, 653-659. (Pubitemid 14079960)
8. Joki N, Hase H, Nakamura R: Onset of coronary artery disease prior to initiation of hemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997; 12: 718-723. (Pubitemid 27170426)
9. Ohtake T, Kobayashi S, Moriya H: High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16: 1141-1148. (Pubitemid 41710326)
10. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-689. (Pubitemid 30167025)
11. Wang LW, Fahim MA, Hayen A, Mitchell RL, Baines L, Lord S, Craig JC, Webster AC: Cardiac testing for coronary artery disease in potential kidney transplant recipients. Cochrane Database Syst Rev 2001; 7: 1-104.
12. Chonchol M, Whittle J, Desbien: Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol 2008; 28: 354-360.
13. Charytan DM, Kuntz RE, Garshick M, Candia S, Khan F, Mauri L: Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int 2009; 75: 80-87.
14. Whalley GA, Marwick TH, Doughty RN, Cooper BA, Johnson DW, Pilmore A, Harris DC, Pollock CA, Collins JF: IDEAL effect of early initiation of dialysis on cardiac structure and function: results from the echo substudy of the IDEAL trial. Am J Kidney Dis 2013; 61: 262-270.
15. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374.
16. McCullough PA, Agrawal V, Danielewicz E, Abela GS: Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1585-1598.
17. Gross ML, Meyer HP, Ziebart H, Rieger P, Wenzel U, Amann K, Berger I, Adamczak M, Schirmacher P, Ritz E: Calcification of coronary intima and media. Clin J Am Soc Nephrol 2007; 2: 121-134.
18. Ragosta M, Samady H, Isaacs RB, Lawrence B, Gimple W, Sarembock AJ, Powers ER: Coronary flow reserve abnormalities in patients with diabetes mellitus who have endstage renal disease and normal epicardial coronary arteries. Am Heart J 2004; 147: 1017-1023. (Pubitemid 38880957)
19. Garland JS, Holden RM, Groome PA, Lam M, Nolan RL, Morton R, Pickett W: Prevalence and associations of coronary artery calcification in patients with stages 3-5 CKD without cardiovascular disease. Am J Kidney Dis 2008; 52: 849-858.
20. Adragao T, Pires A, Branco P, Castro R, Oliveira A, Nogueira C, Bordalo J, Curto JD, Prata MM: Ankle-brachial index, vascular calcifications and mortality in dialysis patients. Nephrol Dial Transplant 2012; 27: 318-325.
21. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61: 638-647. (Pubitemid 34102607)
22. Campean V, Nonnast-Daniel B, Garlichs C, Gross ML, Amann K: CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Atherosclerosis 2007; 190: 156-166. (Pubitemid 44908310)
23. McGregor E, Jardine AG, Murray LS, Dargie HJ, Rodger RS, Junor BJ: Preoperative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant 1998; 13: 1499-1505. (Pubitemid 28254327)
24. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767. (Pubitemid 33115424)
25. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605. (Pubitemid 44627304)
26. Foley RN, Parfey PS, Harnett JD, Kent GM, Martin GJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
27. Foley RN, Curtis BM, Randell EW, Parfey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2010; 5: 805-813.
28. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H: Does indoxyl sulfate, a uremic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31: 1771-1779.
29. McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, Baker CSR, Camici PG: Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008; 3: 19-26.
30. Parfey PS, Harnett JD, Foley RN: Heart failure and ischemic heart disease in chronic uremia. Curr Opin Nephrol Hypertens 1995; 4: 105-110.
31. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM: Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63: 852-1860.
32. Bogrov AY, Shapiro JI: Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 2008; 4378-4392.
33. Wali RK, Wang GS, Gottlieb SS, et al: Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005; 45: 1051-1060. (Pubitemid 40432438)
34. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9: 1018-1022.
35. Raine AEG, Seymour AML, Roberts AFC, Radda GK, Ledingham JGG: Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993; 92: 2934-2940. (Pubitemid 24006564)
36. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586.
37. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5: 39-44. (Pubitemid 20105635)
38. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Lats-cha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Steg-mayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and inter individual variability. Kidney Int 2003; 63: 1934-1943.
39. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R: Inconsistency of reported uremic toxin concentrations. Artif Organs 2007; 31: 600-611. (Pubitemid 47101111)
40. Miyazaki T, Ise M, Seo H, Niwa T: Indoxyl sulfate increases the gene expressions of TGF-β #inf#1#/inf#, TIMP-1 and pro-α1(I) collagen in uremic rat kidneys. Kidney Int Suppl 1997; 62:S15-S22. (Pubitemid 27489395)
41. Milting H, Ellinghaus P, Seewald M: Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27: 589-596. (Pubitemid 351715387)
42. Sharma UC, Pokharel S, van Brakel TJ: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contribute to cardiac dysfunction. Circulation 2004; 110: 3121-3128. (Pubitemid 39492008)
43. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99: 323-328.
44. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, Chao CL, Wang SS, Hsein YC, Liao LC, Ho YL, Chen MF: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009; 409: 96-99.
45. Gopal DM, Kommineni M, Ayalon N, Koelbl C, Ayalon R, Biolo A, Dember LM, Downing J, Siwik DA, Liang CS, Colucci WS: Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 2012; 1: 1-7.
46. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Ken-trup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
47. Gutiérrez OM, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215. (Pubitemid 41716454)
48. Shimada T: Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585.
49. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar AS, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.